Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Genistin is the **7-O-beta-D-glucoside form of genistein**, a naturally occurring isoflavone glycoside primarily found in soybeans and other legumes. It serves as the main dietary source of genistein, with genistin being converted to genistein (the aglycone) during fermentation or digestion of soy products. Genistin itself is structurally characterized by a genistein molecule attached to a glucose moiety at position 7. Its pharmacological properties are thus largely mediated by conversion to genistein in vivo, which is recognized for **phytoestrogenic, anti-inflammatory, and antioxidant effects**, among others. Genistein (and thus genistin) has been studied in relation to cardiovascular disease, osteoporosis, menopausal symptoms, and cancer prevention, primarily due to its ability to modulate estrogen receptors and inhibit tyrosine kinases and topoisomerase II. Genistin itself is not marketed as a standalone pharmaceutical; its relevance is as a dietary component or supplement, and as a precursor to genistein[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on genistin.